Ahead of the market opening on Friday, February 7, analysts from domestic brokerages have recommended several stocks for ...

Zydus Lifesciences share prices showed an increase of more than 2 per cent during the early market hours, following the release of its Q3FY25 results the previous day.  For the relevant quarter, it ...

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which ...

After trading low on the day of its Q3FY25 results announcement, the shares showed positive momentum today by trading over 2% ...

US formulation sales for Zydus Life during the quarter stood at $285 million, which is a growth of 29% on a year-on-year ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

The lineup of major companies declaring their third-quarter results features Asian Paints, Titan, Tata Power, Godrej ...

Market experts have recommended more several stocks to BUY tomorrow (February 3). The top recommendations are Zydus Life, ...

LifeMD generates solid revenue growth but trades at a 1.08x sales multiple. Find out why LFMD stock’s preferreds offer ...

Paragon 28 shares rose 8.4% after Zimmer Biomet Holdings agreed to acquire the company. Shares were trading around $13.02. The stock is up about 2.6% over the last year.

Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...